FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising an aptamer DNA oligonucleotide specifically binding to EGFR, characterized by a nucleotide sequence: ACGCACCATTTGTTTAATATGTTTTTTAATTCCCCTTGTGGTGTGT, and a method of producing said aptamer DNA oligonucleotide. Method of producing DNA oligonucleotide involves cutting 5'- and 3'-end sequence of sequence ATCCAGAGTGACGCAGCATTTGTTTAATATGTTTTTTAATTCCCCTTGTGGTGTGTTGTGGACACGGTGGCTTAGT and 16G replacement by 16C, which leads to duplex increase from 5 to 8 nucleotide pairs and its stabilization.
EFFECT: disclosed invention extends the range of agents for binding with EGFR.
2 cl, 4 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DNA-APTAMER GR200, RECOGNIZING EXTRACELLULAR DOMAIN OF EGFR | 2019 |
|
RU2729382C1 |
| MODIFIED DNA-APTAMERS LINKING EXTRACELLULAR DOMAIN EGFR | 2019 |
|
RU2723398C1 |
| MODIFIED 50-LINK DNA-APTAMERS LINKING EXTRACELLULAR DOMAIN EGFR | 2019 |
|
RU2736790C1 |
| DNA-APTAMERS INTERACTING WITH PROTHROMBIN | 2018 |
|
RU2703799C1 |
| NUCLEIC ACID COMPOUNDS FOR BINDING GROWTH DIFFERENTIATION FACTOR 11 | 2015 |
|
RU2708170C2 |
| METHOD FOR SELECTION AND PRODUCTION OF SELECTIVE AND MULTISPECIFIC THERAPEUTIC MOLECULES WITH SPECIFIED PROPERTIES, INCLUDING, AT LEAST TWO, DIFFERENT TARGET GROUPS, AND THEIR APPLICATIONS | 2013 |
|
RU2644263C2 |
| DNA-APTAMER WITH HIGH AFFINITY TO INTERLEUKIN-6 PROTEIN | 2023 |
|
RU2814541C2 |
| DNA APTAMER THAT SPECIFICALLY BINDS TO HUMAN DICKKOPF-1 PROTEIN | 2023 |
|
RU2814580C1 |
| THERAPEUTIC ANTIBODY SPECIFIC TO INTERLEUKIN-11, INHIBITING SIGNALING THROUGH ITS RECEPTOR, AND METHOD FOR ITS USE FOR THE TREATMENT OF PATIENTS | 2019 |
|
RU2753973C2 |
| THERMAL DISSOCIATION METHOD FOR SELECTION OF DNA-APTAMERS | 2019 |
|
RU2723373C1 |
